On November 6, 2018, CBC's headline "Diabetes Canada warns of 'epidemic,' calls for national strategy" was a stark reminder of the importance of this topic.
It is not very often you see a stock trading at around 60% of the Morningstar value but MNKD is just that. You likely have not heard of this company and that is once again your CannaInvestor Magazine advantage. Why pay hundreds of dollars to subscribe to a service just to be told what companies to invest in based on those those very companies paying to be promoted? MNKD is not cutting them cheques so they are are not raising awareness of this company.
For those of you who subscribe to our Canadian edition, a case study on DAVIDsTEA (DTEA) appears in that edition. This case study on MannKind Corporation (MNKD) also appears in the Canadian edition because we encourage our Canadian edition subscribers to consider US based companies.
MNKD is not directly in the cannabis industry as at time of writing. MNKD serves as a useful case study because it has a potentially game changing delivery system and we will build from there. MNKD is known for its potentially life changing diabetes inhaled technology.
Diabetes is a medical condition believed by many to be advanced or caused by chronic inflammation.
MannKind Corporation
DAQ:MNKD
As at November 1, 2018
Net Shares Outstanding: 158,740,000 (NASDAQ REFERENCE)
Share Price: USD$1.92
Website: http://www.mannkindcorp.com/
MNKD’s Option Chain – CLICK HERE
REUTERS’ RECOMMENDATION
MORNINGSTAR REPORT (UNDERVALUED)
308